Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.3236
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1413913233069.2798
- FreeCF/Share 14.1116
- PFCF 22.5372
- PE 13.6273
- Debt/Assets 0.1976
- DivYield 0.0245
- ROE 0.6695
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVO | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
News
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.
Read More
This Beaten-Down Stock Just Jumped By 8%. Time to Buy?
Published: December 29, 2025 by: The Motley Fool
Sentiment: Positive
Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market.
Read More
Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs
Published: December 26, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S secured FDA approval for oral Wegovy, marking a pivotal expansion in the obesity treatment market. Oral GLP-1 therapies promise greater accessibility and a potentially larger addressable market compared to injectables. NVO's obesity segment, though less reimbursed than diabetes, is growing rapidly at 41% year over year versus 10% for diabetes.
Read More
Bear of the Day: Novo Nordisk (NVO)
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk ( NVO ) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. Based in Bagsværd, Denmark the company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Read More
Focus: Lilly, Novo lock horns in India's obesity drug race
Published: December 23, 2025 by: Reuters
Sentiment: Neutral
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Read More
Final Trade: NVO, FCX, BA, CLF
Published: December 23, 2025 by: CNBC Television
Sentiment: Neutral
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Read More
Launch of Wegovy pill is core to Novo Nordisk's growth, says Guggenheim's Seamus Fernandez
Published: December 23, 2025 by: CNBC Television
Sentiment: Positive
Guggenheim's Seamus Fernandez joins 'Fast Money' to talk Novo Nordisk getting Wegovy pill approved.
Read More
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly's Looming Pill?
Published: December 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk ‘s ( NYSE:NVO ) Wegovy weight-loss pill, the first of its kind.
Read More
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
Read More
Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs?
Published: December 23, 2025 by: Investopedia
Sentiment: Positive
Could a new weight-loss pill be just what Novo Nordisk (NVO) needs to revive its stock?
Read More
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Read More
Novo Nordisk Stock Soars on FDA-Cleared GLP-1 Pill
Published: December 23, 2025 by: Schaeffers Research
Sentiment: Positive
Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from the U.S. Food & Drug Administration (FDA) for the first ever GLP-1 pill.
Read More
Novo CEO Says Wegovy Pill Is Safe and Will Be Widely Available
Published: December 23, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Novo Nordisk President and CEO Mike Doustdar says Christmas has come early with US approval of its Wegovy weight loss pill. He says the company is going "all-in" and they are super excited to be the first to market.
Read More
These 5 Stocks Are Set To Dominate 2026
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Europe, offering geographic diversification. The featured stocks all show significant undervaluation potential based on rather conservative growth scenarios.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
Read More
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
Read More
Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema
Published: December 18, 2025 by: WSJ
Sentiment: Positive
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Published: December 16, 2025 by: CNBC
Sentiment: Positive
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Read More
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Read More
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
Read More
EU drugs regulator backs higher dose of Novo's Wegovy
Published: December 12, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
Read More
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
Published: December 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Read More
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
Read More
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap decline stems from a series of adverse events, some justified but many overdone, with the market ignoring positive developments. Despite recent underperformance versus Eli Lilly, NVO maintains industry-leading margins, robust cash flow, and strong growth prospects, notably with oral GLP-1 candidates.
Read More
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Published: December 02, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo's studies had design flaws.
Read More
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now trading at a forward P/E of 13.5x, well below historical and sector averages, presenting a de-risked entry point. Zaltenibart targets rare, high-value indications like PNH and complement-mediated nephropathies, offering multi-billion dollar TAM if Phase 3 data prove compelling.
Read More
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406